Novartis logo - luca dezzani

Data presented by Novartis showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

June 10, 2016 Novartis has announced Phase III data from RESPONSE-2 revealing that Jakavi®(ruxolitinib) assisted patients with polycythemia vera (PV), who were resistant to or intolerant of hydroxyurea and did not have an enlarged spleen, achieve superior hematocrit control compared to best available therapy (BAT) at 28 weeks (62.2% vs 18.7%, respectively; p<0.0001). These findings … Continue reading Data presented by Novartis showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)

Advertisements
Sanofi Aventis Igea Luca Dezzani

Sanofi to launch dengue mass vaccination program

  April 4, 2016 French multinational pharmaceutical company Sanofi launched the world’s first mass vaccination program for dengue fever in the Philippines on Monday, April 4, 2016. The program brought to fruition a 20-year development process in which the company has invested €1.5bn. The target is to immunize one million Filipino schoolchildren against the virus … Continue reading Sanofi to launch dengue mass vaccination program

abpro Igea Luca Dezzani

Abpro Announces Partnership and Investment with Essex Bio for Development of Antibody Therapeutics

APRIL 6, 2016 Abpro, a Massachusetts-based integrated life science company at the forefront of synthetic biology, has announced a partnership with Essex Bio, a biopharmaceutical company based in China. It has been agreed that Abpro and Essex will jointly develop multiple monoclonal antibodies in ophthalmology and immuno-oncology by leveraging the DiversImmune™ platform of Abpro. Moreover, … Continue reading Abpro Announces Partnership and Investment with Essex Bio for Development of Antibody Therapeutics

Novartis logo - luca dezzani

New Clinical Results show Novartis’ Entresto™ reduced cardiovascular death or hospitalization for heart failure

April 2, 2016 New clinical analysis shows Novartis' Entresto™ reduced cardiovascular (CV) death or hospitalization for heart failure, steadily benefitting patients with reduced ejection fraction (HFrEF) regardless of prior hospital admissions due to heart failure or background therapy. The analysis showed that Entresto benefited patients considered clinically stable, with no history or only a remote … Continue reading New Clinical Results show Novartis’ Entresto™ reduced cardiovascular death or hospitalization for heart failure

GSK Returns to War against Cancer

April 3, 2016 It looked like the UK pharmaceuticals group GlaxoSmithKline (GSK) was declaring surrender in the war on cancer when the company agreed to sell its oncology drugs for $16 billion to Novartis in 2014. However, after two years, GSK returns to this war on cancer again. Axel Hoos, the head of oncology R&D … Continue reading GSK Returns to War against Cancer

Pfizer logo

Pfizer Announces Positive Results from The Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

http://www.workingmother.com/sites/workingmother.com/files/images/2015/08/pfizer_rgb_pos_canvassed.jpg April 5, 2016 Pfizer Inc. in U.S. has announced positive results from its first phase 3 study investigation of tofacitinib for treating adult patients with psoriatic arthritis. The Oral Psoriatic Arthritis trial (OPAL) Broaden  study evaluated the safety and efficacy of tofacitinib 5 mg and 10 mg twice daily (BID) in adult patients with … Continue reading Pfizer Announces Positive Results from The Trial of Investigational Tofacitinib in Adults with Psoriatic Arthritis

takeda logo

New Research Findings on the Efficacy of Long-Term Vedolizumab Treatment

March 19, 2016 Takeda Pharmaceutical Company Limited of Japan announced recently that during the 2016 European Crohn's and Colitis Organisation (ECCO) Annual Scientific Meeting in Amsterdam, the interim findings from the GEMINI Long-term Safety (LTS) study were presented. The findings revealed that patients suffering from moderately to severely active ulcerative colitis (UC) reported clinical improvements … Continue reading New Research Findings on the Efficacy of Long-Term Vedolizumab Treatment

World’s Top Ten Cancer Drugs by 2020

According to the World Health Organization, around 8.2 million people die from cancer every year and it comprises an estimated 13% of all deaths worldwide. It is also predicted by the WHO that there will be a 70% increase in new cases of cancer in the next two decades. Fortunately, many pharma and biotech companies … Continue reading World’s Top Ten Cancer Drugs by 2020

Medical Roles in the Industry: Biologist, Pharmacist and Pharmaceutical Physician

It used to be that medical doctors would only accept work in hospitals and clinics. However, due to the rising demand for new treatments and pharmaceutical products, a new breed of physicians has emerged: the pharmaceutical physicians. A pharmaceutical physician is one which is tasked to lead and advise on the development of new treatments … Continue reading Medical Roles in the Industry: Biologist, Pharmacist and Pharmaceutical Physician

10 best pharmaceutical companies 2015

World’s 10 Best Pharma and Biotech Companies of 2015

With $16.3 billion in profits, $131 billion in assets, and $276 billion in market value, Johnson & Johnson takes the crown as the world’s largest drug and biotech company again this year, edging out Pfizer and Swiss giant Novartis once again.